BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 11175856)

  • 1. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
    D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
    Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.
    Jang JW; Boxer RB; Chodosh LA
    Mol Cell Biol; 2006 Nov; 26(21):8109-21. PubMed ID: 16908535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
    Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
    Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors.
    Morrison BW; Leder P
    Oncogene; 1994 Dec; 9(12):3417-26. PubMed ID: 7970700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.
    Boxer RB; Jang JW; Sintasath L; Chodosh LA
    Cancer Cell; 2004 Dec; 6(6):577-86. PubMed ID: 15607962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
    Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
    Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
    Amundadottir LT; Leder P
    Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras OR neu.
    Elson A; Leder P
    J Biol Chem; 1995 Nov; 270(44):26116-22. PubMed ID: 7592814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice.
    Kapoun AM; Shackleford GM
    Oncogene; 1997 Jun; 14(24):2985-9. PubMed ID: 9205106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice.
    Zhuang SM; Wiseman RW; Söderkvist P
    Oncogene; 2002 Aug; 21(36):5643-8. PubMed ID: 12165863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
    Muthuswamy SK; Siegel PM; Dankort DL; Webster MA; Muller WJ
    Mol Cell Biol; 1994 Jan; 14(1):735-43. PubMed ID: 7903421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis.
    Mangues R; Kahn JM; Seidman I; Pellicer A
    Cancer Res; 1994 Dec; 54(24):6395-401. PubMed ID: 7987834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
    Podsypanina K; Li Y; Varmus HE
    BMC Med; 2004 Jun; 2():24. PubMed ID: 15198801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis.
    Mangues R; Symmans WF; Lu S; Schwartz S; Pellicer A
    Oncogene; 1996 Sep; 13(5):1053-63. PubMed ID: 8806695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
    Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
    Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of proto-oncogene activation in carcinogenesis.
    Anderson MW; Reynolds SH; You M; Maronpot RM
    Environ Health Perspect; 1992 Nov; 98():13-24. PubMed ID: 1486840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice.
    Klinakis A; Szabolcs M; Politi K; Kiaris H; Artavanis-Tsakonas S; Efstratiadis A
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9262-7. PubMed ID: 16751266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF beta regulation of cell proliferation.
    Moses HL; Arteaga CL; Alexandrow MG; Dagnino L; Kawabata M; Pierce DF; Serra R
    Princess Takamatsu Symp; 1994; 24():250-63. PubMed ID: 8983080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of oncogene expression by green tea and (-)-epigallocatechin gallate in mice.
    Hu G; Han C; Chen J
    Nutr Cancer; 1995; 24(2):203-9. PubMed ID: 8584456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ.
    Thompson TC; Southgate J; Kitchener G; Land H
    Cell; 1989 Mar; 56(6):917-30. PubMed ID: 2538247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.